Innovative Treatment Platform Amplitude Vascular Systems has developed the Pulse IVL System, a novel pulsatile intravascular lithotripsy technology that effectively treats severely calcified arterial lesions, representing a significant advancement in interventional vascular therapies.

Recent Funding Momentum The company has secured substantial Series B funding multiple times, with recent rounds totaling over 36 million dollars, indicating strong investor confidence and potential for scaling sales and expanding clinical deployments.

Target Market Focus Operating within the medical equipment manufacturing industry and focusing on vascular treatment solutions, AVS presents opportunities to partner with hospitals, cardiology centers, and vascular specialists looking for advanced calcification management devices.

Leadership and Expansion With strategic hires such as a Vice President of Clinical Affairs and a leadership team with clinical and technical expertise, AVS is positioning itself for clinical adoption growth and regulatory approval pathways, making it a promising partner for device adoption programs.

Growth and Revenue Although still in early revenue stages with an estimated $1M to $10M, the company's recent funding and technological innovation suggest a strong potential for rapid market penetration and increased sales in the minimally invasive vascular device sector.